Rani
Develops RaniPill capsules for oral delivery of biologics and drugs.
Something off on this page? Send us feedback.
Profile
Develops RaniPill capsules for oral delivery of biologics and drugs, alongside internal and partner programs. The clinical-stage business has one operating segment, with RaniPill GO and HC configurations and contract revenue rather than a mature product portfolio.
Develops the RaniPill, a swallowable robotic capsule intended to deliver biologics and drugs through the intestinal wall. The platform is designed as an oral alternative to injectable delivery and has two configurations: RaniPill GO for microtablets and RaniPill HC for liquid payloads.
Its internal pipeline includes RT-114, an oral GLP-1/GLP-2 dual agonist, and RT-116, an oral semaglutide program; RT-117 pairs RaniPill HC with a Chugai compound for hemophilia. The company reports one operating segment and contract revenue rather than a mature commercial product portfolio. Development depends on clinical progress and collaborations including ProGen and Chugai.
Company facts
Key statistics
Year to date −38.2% · Average volume (30d) 899.2K
Analysts
Ratings
Target range
Latest analyst notes
No analyst notes in the last 24 months.
Earnings
EPS
Revenue
History
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Next session |
|---|---|---|---|---|---|---|---|
| Aug 13, 2026Q2 FY26 | −$0.05 | −$0.04 | +20.0% | $925.0K | $1.7M | +84.8% | −0.23% |
| May 15, 2026Q1 FY26 | −$0.06 | −$0.04 | +33.3% | $1.1M | $1.7M | +51.8% | −9.97% |
| Mar 26, 2026Q4 FY25 | −$0.03 | −$0.07 | −133.3% | $5.0M | $1.5M | −70.8% | −24.94% |
| Nov 6, 2025Q3 FY25 | −$0.09 | −$0.12 | −33.3% | $5.0M | — | — | −11.01% |
Financial highlights
| 12 quarters | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | |
|---|---|---|---|---|---|---|---|
| Revenue | $172.0K | $0 | $0 | $1.5M | $1.7M | $1.7M | |
| Gross profit | $172.0K | $0 | $0 | $1.5M | $1.5M | $1.7M | |
| Operating income | −$12.0M | −$10.5M | −$7.3M | −$8.5M | −$8.3M | −$8.8M | |
| Net income | −$7.3M | −$6.7M | −$5.4M | −$10.3M | −$7.0M | −$7.4M | |
| Diluted EPS | −$0.22 | −$0.18 | −$0.12 | −$0.07 | −$0.04 | −$0.04 | |
| Gross margin | 100.0% | — | — | 100.0% | 90.6% | 100.0% | |
| Operating margin | -6,984.3% | — | — | -584.2% | -488.2% | -516.9% |
Fiscal years (4-quarter sums)FY21 $2.7M · FY22 $0 · FY23 $0 · FY24 $1.0M · FY25 $1.6M
Balance sheet, Jun 30, 2026Cash & short-term investments $53.4M · Total debt $3.5M · Total assets $60.8M · Shareholders' equity $39.2M
Dividends
No dividends on record.
Ownership
Shares outstanding 65.32M · Float 47.14M · 72.2% free float
Top shareholders13F · 13D/G · Form 4
| Holder | Shares | % outstanding | Form | Filed |
|---|---|---|---|---|
| Srinivas Akkaraju | 11.32M | 9.90% | 13D | May 28, 2026 |
| Invus Public Equities, L.P. | 8.62M | 8.80% | 13G | Oct 23, 2025 |
| Ra Capital Management, L.P. | 8.50M | 13.01% | 13F | May 15, 2026 |
| Samsara Biocapital, LLC | 8.50M | 13.01% | 13F | May 15, 2026 |
| Awm Investment Company, Inc. | 6.50M | 9.95% | 13F | May 15, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Jul 21, 2026 | Mir A. Imran | director, 10 percent owner: | +36,000 | $0.6900 |
| Dec 27, 2024 | Talat Imran | director, officer: Chief Executive Officer | −8,014 | $1.41 |
| Jul 17, 2026 | Talat Imran | director, officer: Chief Executive Officer | +35,000 | $0.7198 |
| Mar 27, 2026 | Alireza Javadi | officer: Chief Technical Officer | −386 | $0.7800 |
| Oct 23, 2025 | Mir A. Imran | director, 10 percent owner: | +4,166,668 | $0.5425 |
Peers
- Novo Nordisk (ADR)
Oral and injectable GLP-1 therapies in obesity
- Eli Lilly
Injectable incretin therapies in obesity
- Entera Bio
Oral peptide delivery and obesity programs
- Lexaria Bioscience
Oral GLP-1 formulation technology
- AbbVie
Injectable biologics versus oral delivery
- Johnson & Johnson
Injectable biologic therapies versus oral delivery
CompareAfter-hours close
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Rani | $0.8703 | +3.59% | $54.9M | — | — | 11.3 | — |
| Novo Nordisk (ADR) | $45.60 | +0.00% | $202.54B | 11.2 | 18.4 | 4.0 | +0.0% |
| Eli Lilly | $1,173.00 | −0.08% | $1.10T | 39.4 | 28.7 | 13.9 | +47.7% |
| Entera Bio | $3.03 | −0.33% | $149.3M | — | — | — | — |
| Lexaria Bioscience | $10.30 | −1.03% | $17.1M | — | — | 88.2 | −88.5% |
| AbbVie | $255.80 | +0.13% | $451.38B | 72.0 | 16.8 | 7.0 | +10.2% |
| Johnson & Johnson | $268.40 | +0.13% | $645.95B | 31.1 | 22.4 | 6.6 | +6.6% |
| Median | 35.2 | 20.4 | 7.0 | +6.6% |